Vivimed Labs Ltd.

NSE: VIVIMEDLAB BSE: 532660 SECTOR: Pharmaceuticals & Drugs  46k   48   6

5.86
-0.08 (-1.35%)
NSE: 29 May 4:00 PM

Price Summary

Today's High

₹ 6.2

Today's Low

₹ 5.7

52 Week High

₹ 13.8

52 Week Low

₹ 5.6

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

48.59 Cr.

Enterprise Value

398.75 Cr.

No. of Shares

8.29 Cr.

P/E

0

P/B

0.14

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  42.95

CASH

6.78 Cr.

DEBT

356.94 Cr.

Promoter Holding

20.94 %

EPS (TTM)

₹  -9.86

Sales Growth

3.96%

ROE

-14.96 %

ROCE

-3.18%

Profit Growth

-191.04 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year3.96%
3 Year-4.64%
5 Year-17.46%

Profit Growth

1 Year-191.04%
3 Year-322.08%
5 Year-188.28%

ROE%

1 Year-14.96%
3 Year-7.75%
5 Year-4.04%

ROCE %

1 Year-3.18%
3 Year0.58%
5 Year2.79%

Debt/Equity

0.8513

Price to Cash Flow

1.92

Interest Cover Ratio

-0.635271600896522

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 20.94 37.06
Dec 2022 20.96 37.11
Sep 2022 20.96 37.11
Jun 2022 20.96 37.11
Mar 2022 21.98 40.02
Investors List
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor profit growth of -322.077248546919% for the Past 3 years.
  • The company has shown a poor revenue growth of -4.63862714898026% for the Past 3 years.
  • Company has a poor ROE of -7.75169089621593% over the past 3 years.
  • Promoter pledging has increased from 20.94% to 37.06% in 1 quarter.
  • Company has a poor ROCE of 0.575897116831397% over the past 3 years
  • Company has low Interest coverage ratio of -0.635271600896522.
  • Company has contingent liabilities of 215.573 Cr.
  • Promoter pledging is high as 37.06%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 51.9 53.12 47.36 39.18 50.56
Total Expenditure 59.38 54.8 55.89 48.89 56.72
Operating Profit -7.47 -1.68 -8.53 -9.71 -6.16
Other Income -0.36 0.56 0.08 0.15 0.01
Interest 11.53 10.01 9.26 8.79 9.16
Depreciation 4.27 4.66 4.23 3.8 3.8
Exceptional Items 0 0 0 0 0
Profit Before Tax -23.63 -15.79 -21.94 -22.16 -19.12
Tax 0 2.82 -0.05 0 0
Profit After Tax -23.63 -18.6 -21.89 -22.16 -19.12
Adjusted EPS (Rs) -2.85 -2.24 -2.64 -2.67 -2.31

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 261.39 251.81 276.61 210.05 218.37
Total Expenditure 183.05 184.32 243.87 182.13 227.4
Operating Profit 78.34 67.49 32.73 27.92 -9.04
Other Income 1.93 8.54 6.54 6.14 1.26
Interest 53.27 52.63 43.44 41.78 39.71
Depreciation 18.14 18.26 16.57 15.8 17.45
Exceptional Items 0 0 0 0 0
Profit Before Tax 8.85 5.13 -20.74 -23.51 -64.94
Tax -1.02 -1.06 -1.57 -0.23 2.82
Net Profit 9.87 6.19 -19.17 -23.28 -67.75
Adjusted EPS (Rs.) 1.2 0.75 -2.31 -2.81 -8.17

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 16.51 16.51 16.58 16.58 16.58
Total Reserves 550.9 556.12 537.31 507.88 440.69
Borrowings 115.96 89.71 67.97 57.1 60.61
Other N/C liabilities 172.33 153.7 144.32 183.26 188.08
Current liabilities 399.72 338.52 301.14 330 365.98
Total Liabilities 1255.41 1154.56 1067.32 1094.83 1071.95
Assets
Net Block 404.83 380.7 356.42 416.5 428.81
Capital WIP 42.78 64.18 69.77 58.45 40.03
Intangible WIP 0 0 0 0 0
Investments 151.87 87.53 87.5 161.14 161.14
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 655.94 622.14 553.63 458.75 441.98
Total Assets 1255.41 1154.56 1067.32 1094.83 1071.95
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 8.85 5.13 -20.74 -29.42 -64.38
Adjustment 69.62 62.82 59.57 57.29 56.98
Changes in Assets & Liabilities 144.61 40.36 42.23 154.15 32.71
Tax Paid -16.54 -26.26 -6.03 -2.49 0
Operating Cash Flow 206.55 82.04 75.02 179.52 25.31
Investing Cash Flow -38.12 56.17 3.32 -138.2 -11.34
Financing Cash Flow -174.8 -123.23 -91.42 -46.4 -13.21
Net Cash Flow -6.38 14.98 -13.07 -5.07 0.76

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 21.98 20.96 20.96 20.96 20.94
bbr projects priva... 11.45 11.45 11.45 11.45 11.45
santosh varalwar 2.60 1.58 1.58 1.58 1.57
varalwar sandeep 2.26 2.26 2.26 2.26 2.26
varalwar sandeep - - - - -
sujatha varalwar 0.48 0.48 0.48 0.48 0.48
manohar rao varalw... 1.25 1.25 1.25 1.25 1.25
varalwar subhash 1.95 1.95 1.95 1.95 1.95
varalwar subhash - - - - -
vithabai varalwar 0.03 0.03 0.03 0.03 0.03
sheetal varalwar 0.69 0.69 0.69 0.69 0.69
s raghunandan 0.38 0.38 0.38 0.38 0.38
madhavi varalwar 0.24 0.24 0.24 0.24 0.24
madhavi varalwar - - - - -
mamatha gurnukar 0.18 0.18 0.18 0.18 0.18
vijaykumar varalwar 0.18 0.18 0.18 0.18 0.18
mamatha gurnurkar - - - - -
neelima vijaya var... 0.12 0.12 0.12 0.12 0.12
satish gooty agrah... 0.07 0.07 0.07 0.07 0.07
chandrashekharrao ... 0.06 0.06 0.06 0.06 0.06
varalwar padma 0.04 0.04 0.04 0.04 0.04
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 78.02 79.04 79.04 79.04 79.06
kitara piin 1102 9.53 9.53 - 9.37 9.37
sbicap securities ... 1.82 - - - -
sameer mahendra sa... 1.64 1.64 - 1.64 1.64
william f harvey 1.65 1.65 - 1.65 1.65
tushar rameshchand... - - - - -
kitara piin 1101 - - - - -
k india opportunit... 1.47 1.47 1.47 1.47 1.47

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Vivimed Labs informs about disclosure3 Apr 2023, 4:47PM Vivimed Labs informs about board meeting3 Mar 2023, 12:43PM Vivimed Labs - Quaterly Results13 Feb 2023, 6:05PM Vivimed Labs informs about board meeting 27 Oct 2022, 5:00PM Vivimed Labs informs about certificate15 Jul 2022, 12:01PM Vivimed Labs informs about disclosure of related party transactions 18 Jun 2022, 11:25AM Vivimed Labs informs about updates 13 Jun 2022, 4:58PM Vivimed Labs informs about outcome of board meeting4 Jun 2022, 9:46AM Vivimed Labs informs about board meeting18 May 2022, 5:00PM Vivimed Labs informs about loss of share certificates13 May 2022, 3:29PM Vivimed Labs informs about disclosure4 Apr 2022, 2:57PM Vivimed Labs informs about disclosure1 Feb 2022, 10:32AM Vivimed Labs informs about trading window closure27 Dec 2021, 4:23PM Vivimed Labs informs about cancellation of existing book closure13 Sep 2021, 12:22PM Vivimed Labs informs about certificate16 Jul 2021, 12:46PM Vivimed Labs informs about board meeting16 Jun 2021, 4:25PM Vivimed Labs informs about press release25 May 2021, 9:34AM Vivimed Labs exports first shipment of Famotidine tablets to Canada24 May 2021, 2:52PM Vivimed Labs informs about compliance certificate21 Apr 2021, 3:50PM Vivimed Labs gets approvals for 3 products from Hyderabad manufacturing site17 Apr 2021, 8:51AM Vivimed Labs informs about approval of products16 Apr 2021, 4:01PM Vivimed Labs gets approval from Uzbekistan government for two products8 Mar 2021, 2:04PM Vivimed Labs gets approval for 1 product from Uzbekistan Government22 Feb 2021, 2:05PM Vivimed Labs informs about demise independent director2 Dec 2020, 10:39AM Vivimed Labs gets nod for 3 ophthalmic products, 3 oral liquid suspension products23 Nov 2020, 11:46AM Vivimed Labs informs about certificate17 Oct 2020, 3:45PM Vivimed Labs receives approvals for ophthalmic, oral liquid suspension products 13 Oct 2020, 9:57AM Vivimed Labs informs about e-voting8 Oct 2020, 10:36AM Vivimed Labs receives export order for supply of Favulous tablets 6 Aug 2020, 9:00AM Vivimed Labs informs about compliance certificate 18 Jul 2020, 11:50AM Vivimed Labs informs about disclosure16 May 2020, 10:23AM

Vivimed Labs Stock Price Analysis and Quick Research Report. Is Vivimed Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Vivimed Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 25.306 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Vivimed Labs has a Debt to Equity ratio of 0.8513 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Vivimed Labs , the EPS growth was -191.042171249466 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Vivimed Labs has OPM of -4.13798788278449 % which is a bad sign for profitability.
     
  • ROE: Vivimed Labs have a poor ROE of -14.9605681977519 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Vivimed Labs

X